Immunogenicity of Pasteurella multocida and Mannheimia haemolytica outer membrane vesicles

Sandro Roier1, Judith C Fenninger, Deborah R Leitner

  • 1Institute of Molecular Biosciences, University of Graz, Humboldtstraße 50, A-8010 Graz, Austria.

Insights

Outer membrane vesicles (OMVs) from Pasteurella multocida and Mannheimia haemolytica induce strong immune responses in mice. These OMVs show potential for developing broad-spectrum vaccines against bovine respiratory disease (BRD) and other infections.

Area of Science:

  • Veterinary immunology
  • Bacteriology
  • Vaccine development

Background:

  • Pasteurella multocida and Mannheimia haemolytica cause significant diseases in animals, including bovine respiratory disease (BRD).
  • Current vaccines offer limited protection against P. multocida and M. haemolytica infections.
  • There is a need for improved vaccines against these economically important pathogens.

Purpose of the Study:

  • To characterize the immunogenicity of P. multocida and M. haemolytica outer membrane vesicles (OMVs).
  • To evaluate the potential of OMVs for developing cross-protective vaccines against BRD.

Main Methods:

  • Intranasal immunization of BALB/c mice with P. multocida and M. haemolytica OMVs.
  • Enzyme-linked immunosorbent assays (ELISA) to assess humoral and mucosal immune responses.
  • Colonization studies, immunoblot, and immunoprecipitation analyses to identify immunogenic antigens.

Main Results:

  • OMVs from both bacteria induced robust homologous immune responses.
  • Significant cross-immunogenicity was observed between P. multocida and M. haemolytica OMVs.
  • M. haemolytica OMVs elicited a more complex immune response than P. multocida OMVs.
  • Key immunogenic proteins were identified for both P. multocida (OmpA, OmpH, P6) and M. haemolytica (serotype 1-specific antigen, P2, OmpA).

Conclusions:

  • P. multocida and M. haemolytica OMVs are potent immunogens.
  • OMVs can induce cross-protective immunity, offering a promising strategy for BRD vaccine development.
  • Identification of key antigens will aid in designing next-generation OMV-based vaccines.

Related Concept Videos